PURPOSE: The aim of this study was to evaluate the capability of biomarkers to predict the risk of oral mucositis in head and neck cancer patients, as well as to assess the correlation between these biomarkers and the severity of mucositis. METHODS: The search was performed at LILACS, PubMed, Science Direct, Scopus, and Web of Science. A search of the gray literature was performed on Google Scholar, OpenGrey, and ProQuest. The methodological quality of the included studies was assessed using the Meta-Analysis of Statistics Assessment and Review Instrument (MAStARI) tool, and the evidence quality was assessed by the Grading of Recommendation, Assessment, Development, and Evaluation (GRADE) system. RESULTS: After a two-step selection process, 26 studies met the eligibility criteria. In total, 27 biomarkers were evaluated, and the most frequent were the epidermal growth factor (EGF), C-reactive protein (CRP), genetic polymorphisms, tumor necrosis factor alpha (TNF-α), and erythrocyte sedimentation rate (ESR). The meta-analysis showed an expression of polymorphisms in XRCC1 (32.66%), XRCC3 (31.00%), and RAD51 (39.16%) genes, as well as an expression of protein biomarkers (39.57%), in patients with an increased risk of developing oral mucositis. CONCLUSIONS: Dosing biomarkers before starting radiation therapy may be a promising method to predict the risk of developing mucositis and allow radiosensitive patients to have a customized treatment. Although there is currently limited evidence to confirm the putative implementation of serum and salivary biomarkers to assess the correlation between them and the severity of mucositis, this current review provides new research directions.
PURPOSE: The aim of this study was to evaluate the capability of biomarkers to predict the risk of oral mucositis in head and neck cancerpatients, as well as to assess the correlation between these biomarkers and the severity of mucositis. METHODS: The search was performed at LILACS, PubMed, Science Direct, Scopus, and Web of Science. A search of the gray literature was performed on Google Scholar, OpenGrey, and ProQuest. The methodological quality of the included studies was assessed using the Meta-Analysis of Statistics Assessment and Review Instrument (MAStARI) tool, and the evidence quality was assessed by the Grading of Recommendation, Assessment, Development, and Evaluation (GRADE) system. RESULTS: After a two-step selection process, 26 studies met the eligibility criteria. In total, 27 biomarkers were evaluated, and the most frequent were the epidermal growth factor (EGF), C-reactive protein (CRP), genetic polymorphisms, tumor necrosis factor alpha (TNF-α), and erythrocyte sedimentation rate (ESR). The meta-analysis showed an expression of polymorphisms in XRCC1 (32.66%), XRCC3 (31.00%), and RAD51 (39.16%) genes, as well as an expression of protein biomarkers (39.57%), in patients with an increased risk of developing oral mucositis. CONCLUSIONS: Dosing biomarkers before starting radiation therapy may be a promising method to predict the risk of developing mucositis and allow radiosensitive patients to have a customized treatment. Although there is currently limited evidence to confirm the putative implementation of serum and salivary biomarkers to assess the correlation between them and the severity of mucositis, this current review provides new research directions.
Entities:
Keywords:
Biological markers; Head and neck cancer; Meta-analysis; Oral mucositis; Radiotherapy; Systematic review
Authors: Alice Y Ho; David P Atencio; Sheila Peters; Richard G Stock; Silvia C Formenti; Jamie A Cesaretti; Sheryl Green; Bruce Haffty; Karen Drumea; Larisa Leitzin; Abraham Kuten; David Azria; Mahmut Ozsahin; Jens Overgaard; Christian N Andreassen; Cynthia S Trop; Janelle Park; Barry S Rosenstein Journal: Int J Radiat Oncol Biol Phys Date: 2006-07-01 Impact factor: 7.038
Authors: P Wardman; L K Folkes; S M Bentzen; M R Stratford; P J Hoskin; H Phillips; S Jackson Journal: Int J Radiat Oncol Biol Phys Date: 2001-10-01 Impact factor: 7.038
Authors: V N Bhattathiri; T T Sreelekha; P Sebastian; P Remani; R Chandini; T Vijayakumar; M K Nair Journal: Int J Radiat Oncol Biol Phys Date: 1994-05-15 Impact factor: 7.038
Authors: Joke Werbrouck; Kim De Ruyck; Fréderic Duprez; Liv Veldeman; Kathleen Claes; Marc Van Eijkeren; Tom Boterberg; Petra Willems; Anne Vral; Wilfried De Neve; Hubert Thierens Journal: Int J Radiat Oncol Biol Phys Date: 2009-03-15 Impact factor: 7.038
Authors: Rajesh V Lalla; Joanne Bowen; Andrei Barasch; Linda Elting; Joel Epstein; Dorothy M Keefe; Deborah B McGuire; Cesar Migliorati; Ourania Nicolatou-Galitis; Douglas E Peterson; Judith E Raber-Durlacher; Stephen T Sonis; Sharon Elad Journal: Cancer Date: 2014-02-25 Impact factor: 6.860
Authors: Radosław Mlak; Tomasz Powrózek; Anna Brzozowska; Iwona Homa-Mlak; Marcin Mazurek; Paweł Gołębiowski; Grzegorz Sobieszek; Teresa Małecka-Massalska Journal: Support Care Cancer Date: 2019-05-10 Impact factor: 3.603
Authors: Umarevathi Gopalakrishnan; A Sumathi Felicita; Lodd Mahendra; Masroor Ahmed Kanji; Saranya Varadarajan; A Thirumal Raj; Shaikh Mohammed Abdul Feroz; Deepak Mehta; Hosam Ali Baeshen; Shankargouda Patil Journal: Front Bioeng Biotechnol Date: 2021-03-15
Authors: Claudio Pulito; Antonio Cristaudo; Caterina La Porta; Stefano Zapperi; Giovanni Blandino; Aldo Morrone; Sabrina Strano Journal: J Exp Clin Cancer Res Date: 2020-10-07